An observational study in Myeloma, sponsored by Rajshekhar Chakraborty, MD. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-07.
Sponsored by Rajshekhar Chakraborty, MD · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 502 studies in Neoplasms, Plasma Cell with a site in United States — 26 open to participants now, 43 under way, 2 of them phase 3. Neoplasms, Plasma Cell · United States.
Among the 502 studies in Neoplasms, Plasma Cell with a site in United States, this one is the 32nd largest by enrollment of the 42 observational ones that give a count, is one of 7 that started in 2022, is one of 42 observational ones, and was the 477th registered.
710 studies on the registry are indexed under Neoplasms, Plasma Cell; 79 are open to participants now.
Browse Neoplasms, Plasma Cell studies →26 of the 502 studies in Neoplasms, Plasma Cell with a site in United States are open now. Recruiting first, the newest first:
Rutgers, The State University of New Jersey · Sites in United States
Ages 18–110 · Healthy volunteers
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18+
Wake Forest University Health Sciences · Sites in United States
Ages 40–49 · Healthy volunteers
Dana-Farber Cancer Institute · Sites in United States
Ages 18+
University of Maryland, Baltimore · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 58 Neoplasms, Plasma Cell studies recruiting now, 34 (59%) set no upper age limit and 12 (21%) stop at 75 or younger; 4 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
502 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 185 · Phase 2 252 · Phase 3 41 · Phase 4 4
First in 1975; this study’s year is marked. 7 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 36 is below the median of 150 across 83 observational studies indexed under Neoplasms, Plasma Cell.
Median enrollment 33 across the 386 interventional studies, 159 across the 42 observational. Of the 430 that completed or were terminated, 152 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
74 of 502 have an industry lead sponsor. The 10 most frequent:
Rajshekhar Chakraborty, MD is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Rajshekhar Chakraborty, MD has 1 study filed under Neoplasms, Plasma Cell — fewer than ten, so there is no comparison to draw.
13 of the studies in Neoplasms, Plasma Cell with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05745285University of MiamiLeukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care | 2026-11-30 |
| NCT01269593Memorial Sloan Kettering Cancer CenterPET Imaging of Cancer Patients Using 124I-PUH71: A Pilot Study | 2026-12 |
| NCT05336383M.D. Anderson Cancer CenterPhase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma | 2026-12-07 |
| NCT06271252OriCell Therapeutics Co., Ltd.A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study | 2026-12-12 |
| NCT07052916Memorial Sloan Kettering Cancer CenterA Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties | 2026-12-27 |
Add all 13 to your calendar (.ics) → With an account.
Among the 502 studies in Neoplasms, Plasma Cell with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate the sensitivity and accuracy of non-invasive MRD assessment using liquid biopsy (blood draw) and functional imaging (whole body MRI) in participants with new diagnosed and previously treated multiple myeloma. The long-term goal of this study is to investigate whether non-invasive methods for MRD assessment can replace bone marrow aspiration and biopsy in a substantial percentage of participants with multiple myeloma.
There is an unmet clinical need for an easier, non-invasive, and reliable method to perform MRD assessments that can be used in clinical trials and routine practice. The two non-invasive modalities that are most promising for MRD assessment are liquid biopsy to detect circulating tumor cells (CTCs) and functional imaging to detect focal myeloma lesions. However, there are no prospective data on the sensitivity and specificity of non-invasive MRD assessment with respect to the gold standard of bone marrow sampling.
Patients with newly diagnosed or previously treated myeloma who are initiating a new line of therapy will be recruited.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with newly diagnosed and previously treated multiple myeloma will receive bone marrow sampling and functional imaging.
Other: MRD Assessment
MRD assessment includes liquid biopsy and functional imaging. Liquid biopsy will be performed by the Adaptive ClonoSEQ® assay in peripheral blood. Functional imaging will be performed by whole body diffusion-weighted magnetic resonance imaging (WB-DWI).
Sensitivity of non-invasive MRD assessment
MRD assessment includes liquid biopsy and functional imaging.
Time frame: 6 months
Specificity of non-invasive MRD assessment
MRD assessment includes liquid biopsy and functional imaging.
Time frame: 6 months
Sensitivity of two MRD-testing algorithms
Combining liquid biopsy, functional imaging, and bone marrow sampling against the reference of bone marrow sampling in patients
Time frame: 6 months
Specificity of two MRD-testing algorithms
Combining liquid biopsy, functional imaging, and bone marrow sampling against the reference of bone marrow sampling in patients
Time frame: 6 months
Progression Free Survival
The progression-free survival (PFS) will be calculated of patients who are MRD-positive and MRD-negative on each modality (liquid biopsy, functional imaging, and bone marrow sampling)
Time frame: 2 years
Overall Survival
The overall survival (OS) will be calculated of patients who are MRD-positive and MRD-negative on each modality (liquid biopsy, functional imaging, and bone marrow sampling)
Time frame: 2 years
Ran from Sep 2022 to primary completion in Dec 2025, 39 months.
Of 31 observational studies under Neoplasms, Plasma Cell, half reached primary completion within 71 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 148. This study's 39 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Rajshekhar Chakraborty, MD